Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06118099 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision; the decision is not related to any safety concern

Conditions

Hidradenitis

Interventions

DRUG: Amlitelimab
DRUG: Placebo

Sponsor

Sanofi